Literature DB >> 18411188

The antisteroid RU486: its cellular and molecular mode of action.

E E Baulieu1.   

Abstract

RU486 is a very powerful antisteroid hormone compound, with antiprogestin and antiglucocorticosteroid clinical applications. High-affinity binding to the receptor ligand-binding domain results in essentially antagonistic function; however, some agonistlike effects have been observed. This review discusses the implications of recent discoveries concerning hsp90 (heat-shock protein M(r) approximately 90,000)-receptor interaction, receptor-DNA binding, and the involvement of transcription factors in the mechanism of action of RU486.

Entities:  

Year:  1991        PMID: 18411188     DOI: 10.1016/1043-2760(91)90030-q

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  11 in total

1.  Comparison of the effects of antiprogestins RU38486, ZK98299 and ORG31710 on periovulatory hypophysial, ovarian and adrenal hormone secretion in the rat.

Authors:  J E Sánchez-Criado; M Tébar; C Bellido; F H de Jong
Journal:  J Endocrinol Invest       Date:  2000-03       Impact factor: 4.256

2.  Increase of kisspeptin-positive cells in the hypothalamus of a rat model of polycystic ovary syndrome.

Authors:  Mika Kondo; Satoko Osuka; Akira Iwase; Tatsuo Nakahara; Ai Saito; Tomoko Nakamura; Maki Goto; Tomomi Kotani; Fumitaka Kikkawa
Journal:  Metab Brain Dis       Date:  2016-02-11       Impact factor: 3.584

3.  Serum levels of GH, IGF-I, LH and ovarian steroids in cyclic and RU486-treated rats.

Authors:  A Ruiz; M Tébar; A Pérez-Romero; M A Rol de Lama; J E Sánchez-Criado
Journal:  J Endocrinol Invest       Date:  1997-11       Impact factor: 4.256

4.  The in vitro inhibitory action of antiprogestin RU486 on LH and FSH secretion in the absence of progesterone in rats is estrogen-dependent.

Authors:  R Aguilar; C Bellido; D Gonzalez; J C Garrido-Gracia; J E Sánchez-Criado
Journal:  Pituitary       Date:  2000-11       Impact factor: 4.107

5.  Psychosocial Stress, Glucocorticoid Signaling, and Prostate Cancer Health Disparities in African American Men.

Authors:  Leanne Woods-Burnham; Laura Stiel; Shannalee R Martinez; Evelyn S Sanchez-Hernandez; Herbert C Ruckle; Frankis G Almaguel; Mariana C Stern; Lisa R Roberts; David R Williams; Susanne Montgomery; Carlos A Casiano
Journal:  Cancer Health Disparities       Date:  2020

6.  Calcitonin immunostaining in monkey uterus during menstrual cycle and early pregnancy.

Authors:  Hong-Lu Diao; Shi-Jie Li; Hong-Bin Wang; Zeng-Ming Yang
Journal:  Endocrine       Date:  2002-06       Impact factor: 3.633

7.  Relevance of an opioid, noscapine in reducing cystogeneses in rat experimental model of polycystic ovary syndrome.

Authors:  A Priyadarshani
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

8.  Deletion of Lysophosphatidic Acid Receptor 3 (Lpar3) Disrupts Fine Local Balance of Progesterone and Estrogen Signaling in Mouse Uterus During Implantation.

Authors:  Honglu Diao; Rong Li; Ahmed E El Zowalaty; Shuo Xiao; Fei Zhao; Elizabeth A Dudley; Xiaoqin Ye
Journal:  Biol Reprod       Date:  2015-10-07       Impact factor: 4.285

9.  The role of estrogen-dependent progesterone receptor in protein kinase C-mediated LH secretion and GnRH self-priming in rat anterior pituitary glands.

Authors:  R Aguilar; C Bellido; J E Sánchez-Criado
Journal:  J Endocrinol Invest       Date:  2003-06       Impact factor: 4.256

10.  Neurotensin: a neuropeptide induced by hCG in the human and rat ovary during the periovulatory period†.

Authors:  Linah Al-Alem; Muraly Puttabyatappa; Ketan Shrestha; Yohan Choi; Kathy Rosewell; Mats Brännström; James Akin; Misung Jo; Diane M Duffy; Thomas E Curry
Journal:  Biol Reprod       Date:  2021-06-04       Impact factor: 4.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.